Testing depemokimab for COPD with type 2 inflammation
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe COPD and your blood test shows high eosinophils (a type of white blood cell linked to inflammation)
- You have had at least 1 moderate flare-up in the past year and have other risk factors for future flare-ups
- You are a current or former smoker with at least a 10 pack-year smoking history
- You take combination inhaler therapy (like ICS+LABA or LABA+LAMA or triple therapy) for at least 3 months
- You have a BMI of 16 or higher and no other major lung disease like asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
This trial tests a new medicine, depemokimab, given as an injection to help reduce flare-ups (exacerbations) in adults with moderate to severe COPD who have a certain type of inflammation. The goal is to see if it can keep you healthier for longer with fewer serious breathing attacks.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.